Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Restem General Information
RESTEM is a clinical-stage biotechnology company developing off-the-shelf, next-generation cell therapies to modulate the immune system. Its lead product, "Restem-L"—an umbilical cord lining stem cell therapy—has shown promising results in phase 1 trials for idiopathic inflammatory myopathy with significant clinical improvement and steroid reduction. The company has received FDA Fast Track and Orphan Drug Designations for this indication and is initiating a potentially registrational phase 2/3 trial. Additional programs include secretome-based therapies and activated NK cells targeting age-related diseases.
Contact Information
Drug Pipeline
RESTEM-UC
Phase 2Key Partnerships
No major pharmaceutical or biotech partnerships disclosed as of June 2025.
Restem Funding
No funding data available
To view Restem's complete valuation and funding history, request access »